

Spring 5-10-2016

Efforts to reduce impact of media variability on product quality for a commercial perfusion process

Nirel Rillera

BioMarin Pharmaceutical Inc, nrillera@bmrn.com

Kevin Yeh

BioMarin Pharmaceutical Inc

Benjamin Youn

BioMarin Pharmaceutical Inc

Jerome Acuna

BioMarin Pharmaceutical Inc

John Henstrand

BioMarin Pharmaceutical Inc

See next page for additional authors

Follow this and additional works at: http://dc.engconfintl.org/cellculture_xv



Part of the [Biomedical Engineering and Bioengineering Commons](#)

Recommended Citation

Nirel Rillera, Kevin Yeh, Benjamin Youn, Jerome Acuna, John Henstrand, and Sean Forestell, "Efforts to reduce impact of media variability on product quality for a commercial perfusion process" in "Cell Culture Engineering XV", Robert Kiss, Genentech Sarah Harcum, Clemson University Jeff Chalmers, Ohio State University Eds, ECI Symposium Series, (2016). http://dc.engconfintl.org/cellculture_xv/95

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

Authors

Nirel Rillera, Kevin Yeh, Benjamin Youn, Jerome Acuna, John Henstrand, and Sean Forestell

EFFORTS TO REDUCE IMPACT OF MEDIA VARIABILITY ON PRODUCT QUALITY FOR A COMMERCIAL PERFUSION PROCESS

Nirel Rillera, BioMarin Pharmaceutical Inc.
nrillera@bmrn.com

Kevin Yeh, BioMarin Pharmaceutical Inc.
Benjamin Youn, BioMarin Pharmaceutical Inc.
Jerome Acuna, BioMarin Pharmaceutical Inc.
John Henstrand, BioMarin Pharmaceutical Inc.
Sean Forestell, BioMarin Pharmaceutical Inc.

Key Words: raw materials, product quality, perfusion

Strict control of raw materials used in bioprocesses is necessary to ensure consistent product quality. However, use of poorly characterized complex components makes achieving such strict control difficult. A strong correlation between product quality variability among bulk drug substance lots and changes in a complex medium component was observed in a commercial perfusion process. This correlation was subsequently confirmed experimentally at both large and small scales. A multifaceted strategy was applied to investigate and mitigate the impact of the media variability on product quality, which included (1) studies in small scale perfusion bioreactors; (2) development of a simple cell based assay to screen different media component lots; and (3) utilization of advanced analytical techniques to identify components that impact product quality. Small-scale perfusion bioreactors were cultured using media lots whose large-scale performance were known, and results were consistent to large-scale performance, supporting the use of small-scale cultures to resolve large-scale media effects. Given the difficulty of utilizing small-scale perfusion bioreactors to screen media lots, an effort was also made to develop a shake flask protocol capable of resolving large-scale media impact on product quality. To simplify testing even further, proteomic and metabolomic analyses through LC-MS were also performed on media and soy retains. Multivariate analysis identified a number of species that could be used as a chemical fingerprint of desirable large-scale performance, which would simplify media qualifications even further. The continued development of new platforms and assays for screening undefined components improves responsiveness to raw material variability and, in turn, enables better control of product quality of commercial products.